Pivoting at pace

By InnerWorkings

· 1 min. read

Pivoting at pace
Source: InnerWorkings

Pharmaceutical launches face execution challenges that can erode value long before market entry. While billions are invested in drug development and approval timelines narrow, one-third of US launches between 2012 and 2021 missed expectations. Success requires protecting strategy through audience research, messaging, regulatory review, localization and field activation.

Key points

  • Clinical evidence ranks as HCPs' top information need at launch. In a qualitative panel, 15 healthcare professionals ranked clinical trial evidence in their top three priorities, followed by guidelines and safety management.
  • Information gaps often persist even after regulatory approval. Guidelines may remain unupdated, real-world evidence unavailable and comparative data lacking, leaving HCPs asking "How do I use this?" rather than simply understanding what the therapy does.
  • Different HCP segments require tailored communication strategies. Academic physicians and KOLs seek interpretation and comparison of emerging data, while community practitioners need foundational education and practical implementation support for the same therapy.
  • HCPs want increased pre-launch engagement with manufacturers. Panelists requested "more pre-launch engagement, including advisory boards during development, pre-approval intelligence from medical science liaisons, conference proceedings and breaking data."
  • Launch planning should begin years before expected approval. Organizations must identify priority audiences, research markets, establish the therapy's role and prepare content and operating models before regulatory decisions, avoiding last-minute gaps.
  • Measurement should track meaningful progression, not just activity volume. Teams should monitor quality field interactions and evidence engagement rather than rewarding channel volume or passive reach, enabling optimization after launch.

Summarized by MalakyeAI

Links Cited on this Page